Standard Biotools Inc. revenue
Standard Biotools Inc.'s revenue was $85.3m in fiscal 2025, down 6.2% on the year before. Since fiscal 2009 ($25.4m) it has grown at a compound 7.9% a year. Over the last twelve months it was $84.6m.
Revenue history
| Fiscal year | 2009Dec 2009 | 2010Dec 2010 | 2011Dec 2011 | 2012Dec 2012 | 2013Dec 2013 | 2014Dec 2014 | 2015Dec 2015 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 25 | 34 | 43 | 52 | 71 | 116 | 115 | 104 | 102 | 113 | 117 | 138 | 131 | 98 | 106 | 91 | 85 | 85 |
| Growth on the year before | — | +32.1% | +27.7% | +22.1% | +36.0% | +63.6% | −1.5% | −8.9% | −2.4% | +10.8% | +3.8% | +17.8% | −5.5% | −25.0% | +8.6% | −14.4% | −6.2% | — |
| Gross profit | — | — | 43 | 52 | 71 | 116 | 114 | 58 | 52 | 62 | 64 | — | — | 37 | 50 | 45 | 43 | 43 |
| Gross margin | — | — | 99.8% | 99.4% | 99.6% | 99.7% | 99.7% | 55.9% | 51.0% | 54.6% | 54.8% | — | — | 37.8% | 47.4% | 49.3% | 49.9% | 50.5% |
Where the revenue comes from
| Line of business | Revenue | YoY |
|---|---|---|
| Products | $61.7M | ▼ 5.8% |
| Consumables | $36.2M | ▼ 10.6% |
| Instruments | $25.4M | ▲ 2.1% |
| Services and Other Revenue | $23.7M | ▼ 7.5% |
| Service and Other Revenue | $23.7M | ▼ 7.5% |
These categories overlap or exclude eliminations, so shares aren't shown.
| Region | Revenue | Share | YoY |
|---|---|---|---|
| EMEA | $36M | 42.2% | ▲ 0.9% |
| Americas | $30.6M | 35.8% | ▼ 18.3% |
| Asia Pacific | $18.8M | 22.0% | ▲ 4.6% |
From Standard Biotools Inc.'s 10-K filed March 16, 2026, as tagged in the filing. View filing. Indented rows are part of the line above; their share is of that line. In the bars, the faint bar behind is the year before.
Revenue against peers
| Company | Revenue | Growth | 3-year growth a year |
|---|---|---|---|
| Standard Biotools Inc. | $84.6m | -4.8% | -7.1% |
| Harvard Bioscience Inc | $87.8m | -1.1% | -8.4% |
| Codexis, Inc. | $77.7m | 35.9% | -7.8% |
| Burning Rock Biotech Ltd | $75.1m | 4.7% | — |
| Exagen Inc. | $71.1m | 20.8% | 10.3% |
| Personalis, Inc. | $69.7m | -13.3% | 1.2% |
Compare with peers
- Harvard Bioscience Inc revenue
- Codexis, Inc. revenue
- Burning Rock Biotech Ltd revenue
- Exagen Inc. revenue
- Personalis, Inc. revenue
Head to head: HBIO vs LABCDXS vs LABBNR vs LAB
More: Life Sciences Tools & Services stocks compared, Health Care sector, rankings of US companies